CLAIMS

We claim:

1. A compound of Formula I



I

wherein:

A is hydrogen, C_{1-4}alkyl, C_{1-4}aminoalkyl, or a heterocycle selected from the group consisting of  ;

W is NR^3, O, or S;

R^1 is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkyloxy, cyano, trifluoromethyl, and alkoxycarbonyl;

R^2 is C_{1-6}alkyl or C_{3-7}cycloalkyl;

R^3 is hydrogen or C_{1-6}alkyl;

m is 0, 1, 2, or 3;

n is 1 or 2;

X is CO or SO_2;

B is selected from C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylmethyl; C_{1-3}methoxyalkyl, and C_{1-3}phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl,

benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and -N(R^3)$_2$;

or a pharmaceutically acceptable salt or solvate.

2. A compound of claim 1 where the carbon marked with an asterisk is of the (R) stereochemistry.



3. A compound of claim 1 where A is C_{1-4}aminoalkyl, or a heterocycle selected from


,
, and 
.

4. A compound of claim 1 where m is 1 and R^1 is phenyl substituted with 1-2 substituents selected from halo, alkyl, alkyloxy, cyano, carboalkoxy.

5. A compound of claim 1 where X is CO and B is selected from C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylmethyl, C_{1-3}methoxyalkyl, and C_{1-3}phenoxyalkyl or is selected from phenyl, pyrazinyl, furanyl, isoxazolyl, and benzthienyl, moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and -N(R^3)$_2$.

6. A compound of claim 1 where n is 1.

7. The compound of claim 7: N-[1-[(2R)-3-(4-Chlorophenyl)-2-[[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-azetidinyl]-N-cyclohexyl-3-methyl-butanamide.

8. A compound of claim 1 where n is 2.

9. A compound of claim 8 where the carbon marked with an asterisk is of the (S) stereochemistry.



10. A compound of claim 9 selected from the following group:

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

(2S)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(1-oxopentyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(2-furanylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;

N-[1-[(2R)-3-(4-Chlorophenyl)-2-[(3S)-[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-pyrrolidinyl]-N-cyclohexyl-3-methyl-butanamide; and

(3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(methylsulfonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide.

11. A pharmaceutical composition comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

12. A method for treating a patient afflicted with a condition responsive to the modulation of melanocortin receptors comprising administration of a therapeutically effective amount of a compound of claim 1.